Dark

Check out our API

HZNP
Horizon Therapeutics Public Limited Company
stock NASDAQ

Inactive

Oct 5, 2023

116.30USD+0.043%(+0.05)28,881,250

Pre-market

0.00USD-100.000%(-116.25)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

08:11AM EST Horizon Therapeutics plc Announces First Patient Enrolled In Phase 2b Pivotal Trial Evaluating HZN-825 For The Treatment Of Idiopathic Pulmonary Fibrosis Benzinga

08:08AM EST Horizon Says First Patient Enrolled In Phase 2b Trial Evaluating HZN-825 For Idiopathic Pulmonary Fibrosis Treatment RTTNews

08:00AM EST Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Business Wire

Jan 11, 2022

07:47AM EST ACELYRIN Appoints Melanie Gloria As COO RTTNews

07:45AM EST ACELYRIN Appoints Melanie Gloria as Chief Operating Officer PR Newswire

Jan 10, 2022

07:43AM EST Horizon Therapeutics plc Submits Supplemental Biologics License For Concomitant Use Of KRYSTEXXA Plus Methotrexate For People Living With Uncontrolled Gout Benzinga

Jan 6, 2022

08:35AM EST Horizon Reports Significant Expansion Of East Coast Research And Development And Technical Operations Capability RTTNews

08:13AM EST Horizon Therapeutics Reports Expansion Of Its East Coast R&D, Technical Operations Capability: Signed Long-Term Full-Building Lease For Campus In Rockville, Maryland Benzinga

08:00AM EST Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability Business Wire

Dec 23, 2021

08:00AM EST Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire

Dec 16, 2021

08:25AM EST Why Alpine Immune Sciences Is Rising In Pre-market? RTTNews

08:07AM EST Alpine Immune Services, Horizon Therapeutics Report Exclusive License, Collab Deal To Develop Novel Protein-Based Therapies For Autoimmune, Inflammatory Diseases Benzinga

08:07AM EST Alpine Immune Sciences, Horizon To Develop Novel Protein-Based Therapies For Autoimmune And Inflammatory Diseases RTTNews

08:00AM EST Alpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases Business Wire

Dec 8, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 Benzinga

07:26AM EST Wells Fargo Initiates Coverage On Horizon Therapeutics with Overweight Rating, Announces Price Target of $137 Benzinga

Dec 2, 2021

09:00AM EST Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till's Home into a Museum and Theater Business Wire

08:30AM EST Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List Business Wire

Dec 1, 2021

01:34AM EST Horizon Therapeutics Announces $140,000 In Scholarships To Help Economically Disadvantaged Students RTTNews

01:30AM EST Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education Business Wire

Nov 22, 2021

09:32AM EST Horizon Therapeutics plc (HZNP) said a new post hoc analysis of the UPLIZNA N-MOmentum Phase 2/3 pivotal trial showed that prior rituximab exposure did not impact the efficacy of UPLIZNA, and that UPLIZNA demonstrated comparable efficacy to trial participants without prior exposure to rituximab. RTTNews

08:18AM EST Horizon Therapeutics Announces New Analysis Of UPLIZNA N-MOmentum Phase 2/3 Trial On NMOSD RTTNews

08:00AM EST New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA(r) (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire

Nov 19, 2021

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

05:25AM EST Goldman Sachs Upgrades Horizon Therapeutics to Buy, Announces $168 Price Target Benzinga

Nov 15, 2021

09:00AM EST Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative Business Wire

Nov 12, 2021

08:41AM EST Horizon Therapeutics : Real-World Data Show High Rate Of Patient Adherence To TEPEZZA For Thyroid Eye Disease RTTNews

08:33AM EST New Real-World Data Show High Rate of Patient Adherence to TEPEZZA(r) (teprotumumab-trbw) for Thyroid Eye Disease (TED) Business Wire

07:39AM EST Horizon Therapeutics Reports Positive European Medicines Agency Committee For Medicinal Products For Human Use Opinion For UPLIZNA Benzinga

Nov 9, 2021

11:42AM EST Horizon Therapeutics plc Announces First Patient Enrolled In Phase 2b Pivotal Trial Evaluating HZN-825 For The Treatment Of Diffuse Cutaneous Systemic Sclerosis Benzinga

Nov 8, 2021

04:05PM EST Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire

Nov 5, 2021

09:01AM EDT Horizon Therapeutics plc Receives Top Workplace Awards in Chicago and San Francisco Business Wire

Nov 4, 2021

01:02PM EDT Horizon Therapeutics Highlights Presentation Of Results From Completed PROTECT Trial On KRYSTEXXA For Gout At American Society Of Nephrology Kidney Week Benzinga

11:31AM EDT Horizon Therapeutics's Return On Capital Employed Insights Benzinga

Nov 3, 2021

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:16AM EDT Horizon Therapeutics CFO Paul Hoelscher To Retire Effective May 16, Aaron Cox Named Successor Benzinga

09:16AM EDT Horizon Therapeutics Raises FY21 Sales Guidance From $3.025B-$3.125B To $3.16B-$3.21B vs $3.12B Est. Benzinga

09:16AM EDT Horizon Therapeutics Q3 EPS $1.75 Beats $1.54 Estimate, Sales $1.04B Beat $979.41M Estimate Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

07:24AM EDT Horizon Therapeutics CFO Paul Hoelscher To Retire Effective May 16, 2022 RTTNews

07:20AM EDT Horizon Therapeutics Q3 Adj EPS Rises To $1.75 From $1.74 Last Year RTTNews

07:02AM EDT Horizon Therapeutics plc Announces Chief Financial Officer Succession Plan Business Wire

07:00AM EDT Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance Business Wire

Nov 1, 2021

10:02AM EDT Horizon Therapeutics Highlights Data Being Presented At American College Of Rheumatology Convergence 2021; Says Data Shows Co's Commitment To Improving Outcomes For People Living With Uncontrolled Gout Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 25, 2021

08:03AM EDT Horizon Therapeutics Topline Results Met Primary Endpoint For KRYSTEXXA With Methotrexate Benzinga

Oct 22, 2021

09:29AM EDT Horizon Therapeutics plc Named to Newsweek's List of the Most Loved Workplaces for 2021 Business Wire

Oct 21, 2021

12:12PM EDT Horizon Therapeutics Highlights Newly-Published Data On Long-Term Efficacy For Co.'s TEPEZZA For Thyroid Eye Disease In 'Ophthalmology' Benzinga

12:00PM EDT Newly Published Data Continue to Support Long-Term Efficacy of TEPEZZA(r) (teprotumumab-trbw) for Thyroid Eye Disease (TED) Business Wire

Oct 13, 2021

01:38PM EDT Horizon Therapeutics Reports Results From New Analysis Of UPLIZNA Phase 2/3 Trial Showing A Correlation Between Depth Of B-Cell Depletion, Improved Neuromyelitis Optica Spectrum Disorder Patient Outcomes Benzinga

08:00AM EDT New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA(r) (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire

Oct 12, 2021

09:08AM EDT Horizon Therapeutics : TEPEZZA Data To Be Presented At American Academy Of Ophthalmology 2021 Annual Meeting RTTNews

09:00AM EDT New TEPEZZA(r) (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting Business Wire

Oct 11, 2021

08:00AM EDT Horizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021 Business Wire

Oct 6, 2021

08:00AM EDT Horizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption Business Wire

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Oct 4, 2021

08:40AM EDT Horizon Therapeutics : Data Shows Long-term UPLIZNA Use Is Associated With Reduced Risk Of NMOSD Attacks RTTNews

08:30AM EDT New Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA(r) (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire

08:25AM EDT Horizon Therapeutics plc Announces New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be Presented At ECTRIMS 2021 Benzinga

08:15AM EDT Horizon : New UPLIZNA Data In Neuromyelitis Optica Spectrum Disorder To Be Presented At ECTRIMS 2021 RTTNews

08:00AM EDT Horizon Therapeutics plc Announces New UPLIZNA(r) (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021 Business Wire

Oct 1, 2021

01:51PM EDT SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals Benzinga

Sep 29, 2021

07:24AM EDT Horizon Therapeutics Highlights R&D Day Benzinga

07:00AM EDT Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day Business Wire

Sep 23, 2021

09:00AM EDT Horizon Therapeutics plc Announces Agenda for Virtual R&D Day for Investors and Analysts on Sept. 29, 2021 Business Wire

08:55AM EDT Horizon Therapeutics plc (HZNP) reported results of a retrospective analysis of the pivotal Phase 2/3 N-MOmentum trial, indicating UPLIZNA may provide durable efficacy and a favorable safety profile for African Americans with Neuromyelitis Optica Spectrum Disorder. RTTNews

08:36AM EDT Horizon : Data Show UPLIZNA Produces Rapid And Sustained B-Cell Depletion In African Americans With NMOSD RTTNews

08:34AM EDT Horizon Therapeutics Highlights Data Showing UPLIZNA Also Produces B-Cell Depletion In African Americans With Neuromeylitis Optica Spectrum Disorder Benzinga

08:30AM EDT Horizon Therapeutics plc Announces Data Showing UPLIZNA(r) (inebilizumab-cdon) Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire

Sep 21, 2021

08:00AM EDT Horizon Therapeutics plc Announces New Genetic Counselor Curated Algorithms and Next-Generation Sequencing Data as Winning Solutions of First-Ever Horizon Prize, Powered by MIT Solve, to Accelerate Rare Disease Diagnosis Business Wire

07:33AM EDT HemoShear Therapeutics Says Advancing Several Novel Compounds For Horizon Therapeutics plc Gout Discovery Pipeline Benzinga

07:31AM EDT HemoShear Therapeutics Advancing Several Novel Compounds for Horizon PR Newswire

Sep 16, 2021

09:00AM EDT Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women(tm) by Fortune and Great Place to Work(r) Business Wire

Sep 7, 2021

08:43AM EDT Horizon Therapeutics Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA For Treatment of Chronic (Inactive) Thyroid Eye Disease (TED) Benzinga

08:35AM EDT Horizon Therapeutics Begins Randomized Controlled Trial of TEPEZZA For Chronic (Inactive) Thyroid Eye Disease RTTNews

08:30AM EDT Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA(r) (teprotumumab-trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED) Business Wire

Sep 1, 2021

09:10AM EDT Horizon Therapeutics plc Named One of PEOPLE's 100 Companies That Care(r) Business Wire

Aug 26, 2021

10:19AM EDT Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to $135 Benzinga

Aug 24, 2021

07:55AM EDT Goldman Sachs Maintains Neutral on Horizon Therapeutics, Raises Price Target to $107 Benzinga

Aug 23, 2021

04:01PM EDT Horizon Therapeutics plc to Participate in Upcoming Conferences Business Wire

Aug 5, 2021

09:14AM EDT Citigroup Maintains Buy on Horizon Therapeutics, Raises Price Target to $121 Benzinga

08:10AM EDT BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to $132 Benzinga

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

10:56AM EDT Horizon Therapeutics Earlier Raised Its FY21 Sales Guidance From $2.75B-$2.85B To $3.025B-$3.125B Vs. $2.81B Est. Benzinga

10:55AM EDT Horizon Therapeutics Earlier Reported Q2 EPS $1.62 Beats $0.88 Estimate, Sales $832.55M Beat $685.03M Estimate Benzinga

08:08AM EDT Horizon Therapeutics: Q2 Earnings Insights Benzinga

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

07:12AM EDT Horizon Therapeutics Q2 Net Income $158.1 Mln Vs. Net Loss $80.0 Mln Last Year RTTNews

07:00AM EDT Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance Business Wire

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 16, 2021

08:30AM EDT Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials(tm) Business Wire

Jun 30, 2021

08:00AM EDT Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021 Business Wire

Jun 29, 2021

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

08:08AM EDT Horizon Therapeutics Enrolls First Patient In Phase 2 Trial Evaluating HZN-7734 For Systemic Lupus Erythematosus RTTNews

08:00AM EDT Horizon Therapeutics plc Announces First Patient Enrolled In Phase 2 Trial Evaluating HZN-7734 For The Treatment Of Systemic Lupus Erythematosus Benzinga

Jun 28, 2021

09:00AM EDT Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves' Community to FOCUS on Thyroid Eye Disease Business Wire

Jun 21, 2021

11:36AM EDT Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate Benzinga

07:38AM EDT Arrowhead Pharma, Horizon Therapeutics Announce Global Collaboration And License Agreement For ARO-XDH RTTNews

07:31AM EDT Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout; Arrowhead To Receive $40M Upfront Benzinga

07:30AM EDT Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout Business Wire

Jun 18, 2021

12:31PM EDT Horizon Therapeutics Announces Multiple Presentations On Neuromyelitis Optica Spectrum Disorder At the 7th Congress Of European Academy of Neurology Benzinga

Jun 17, 2021

08:25AM EDT OPKO Health Offloads Fill and Finish Manufacturing Facility in Ireland To Horizon Therapeutics Benzinga

07:12AM EDT Horizon Therapeutics Agrees To Purchase A Drug Product Manufacturing Facility From EirGen Pharma In Ireland RTTNews

07:02AM EDT OPKO Health Announces SaleOf iIs Sterile Fill And Finish Manufacturing Facility In Ireland To Horizon Therapeutics For $65M Benzinga

07:00AM EDT Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics Business Wire

Jun 2, 2021

08:17AM EDT Horizon Therapeutics Says Presents New Data On Robust Pipeline At EULAR European Congress Of Rheumatology Benzinga

May 27, 2021

08:01AM EDT Horizon Therapeutics Reports Initiation Of ADVANCE Trial Evaluating KRYSTEXXA With Methotrexate For People Who Previously Developed Anti-Drug Antibodies On KRYSTEXXA Monotherapy Benzinga

May 25, 2021

07:53AM EDT The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal Benzinga

May 24, 2021

08:00AM EDT Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire

May 20, 2021

08:30AM EDT Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago(tm) by Great Place to Work(r) Business Wire

May 13, 2021

11:30AM EDT Horizon Therapeutics plc Ranked #1 in Overall Corporate Reputation Among U.S. Patient Groups that Report Working with the Company Business Wire

May 6, 2021

04:30PM EDT Horizon Therapeutics plc to Present at the Bank of America Securities 2021 Health Care Conference Business Wire

08:34AM EDT Horizon Therapeutics Highlights New Analysis Of UPLIZNA For Neuromyelitis Optica Spectrum Disorder Published In 'Neurology Neuroimmunology & Neuroinflmmation' Benzinga

08:30AM EDT New Analysis of UPLIZNA(r) (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation Business Wire

08:00AM EDT Horizon Therapeutics plc Announces Elizabeth H.Z. Thompson as a Healthcare Businesswomen's Association 2021 Luminary Business Wire

May 5, 2021

08:58AM EDT Horizon Therapeutics Q1 Declines 4% To $342.4 Mln From Last Year; Updates FY Outlook RTTNews

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

07:21AM EDT Recap: Horizon Therapeutics Q1 Earnings Benzinga

07:10AM EDT UPDATE: Horizon Therapeutics Raises FY21 Net Sales Guidance From $2.7B-$2.8B To $2.75B-$2.85B, Adj. EBITDA To $1.02B-$1.06B Benzinga

07:08AM EDT Horizon Therapeutics Q1 Adj. EPS $0.03 Misses $0.04 Estimate, Sales $342.40M Beat $330.73M Estimate; Raises FY21 Sales Guidance Benzinga

07:00AM EDT Horizon Therapeutics plc Reports First-Quarter 2021 Financial Results; Updating Full-Year 2021 Net Sales Guidance and Full-Year Adjusted EBITDA Guidance to Incorporate Recently Acquired Viela Bio, Inc. Business Wire

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

Apr 30, 2021

10:01AM EDT Horizon Therapeutics Says Selects AGC Biologics To Further Supply KRYSTEXXA (Pegloticase Injection) At AGC's Copenhagen Facility Benzinga

Apr 29, 2021

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

Apr 27, 2021

08:00AM EDT Horizon Therapeutics plc Ranks Among the Top Companies in Overall Corporate Reputation in 2020 PatientView Survey of Patient Organizations Worldwide Business Wire

07:41AM EDT The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout Benzinga

Apr 21, 2021

07:34AM EDT Horizon Therapeutics Collaboration Partner HemoShear Therapeutics Identifies Second Drug Target For Gout Benzinga

07:31AM EDT HemoShear Therapeutics Advances Second Novel Drug Target into Horizon PR Newswire

Apr 16, 2021

08:34AM EDT Horizon : Long-term UPLIZNA Treatment Provides Sustained Reduction In NMOSD Attack Risk From Baseline RTTNews

08:32AM EDT Horizon Therapeutics To Present New Long-Term Data For UPLIZNA At American Academy of Neurology's 73rd Annual Meeting Apr. 17-22 Benzinga

08:30AM EDT New Long-Term Data for UPLIZNA(r) (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire

08:06AM EDT Horizon Therapeutics Says New Integrated Data And Follow-up Outcomes From Two TEPEZZA Pivotal Trials Published RTTNews

08:00AM EDT New Integrated Data and Follow-up Outcomes From Two TEPEZZA(r) (teprotumumab-trbw) Pivotal Trials Published in The Lancet Diabetes & Endocrinology Business Wire

Apr 12, 2021

08:30AM EDT Horizon Therapeutics plc Named One of the Fortune 100 Best Companies to Work For(r) Business Wire

Apr 8, 2021

08:00AM EDT Horizon Therapeutics plc to Release First-Quarter 2021 Financial Results and Host Webcast on May 5, 2021 Business Wire

Apr 7, 2021

08:03AM EDT Horizon Therapeutics Highlights Publication Of Data From RECIPE Randomized Controlled Trial In Arthritis & Rheumatology Benzinga

Apr 5, 2021

08:53AM EDT Horizon Therapeutics Says New UPLIZNA Data In People With Neuromyelitis Optica Spetrum Disorder To Be Presented At The American Academy Of Neurology's 73rd Annual Meeting Benzinga

08:30AM EDT New UPLIZNA(r) (inebilizumab-cdon) Data in People With Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the American Academy of Neurology's 73rd Annual Meeting Business Wire

Mar 30, 2021

07:35AM EDT Horizon Therapeutics To Resupply Market With TEPEZZA For Treatment Of Thyroid Eye Disease Beginning In April RTTNews

07:33AM EDT Horizon Therapeutics PLC To Resupply Market With TEPEZZA For The Treatment Of Thyroid Eye Disease Beginning in April Benzinga

07:30AM EDT Horizon Therapeutics plc to Resupply Market With TEPEZZA(r) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Beginning in April Business Wire

Mar 29, 2021

10:05AM EDT Horizon Therapeutics and Chicago Cubs Announce Legacy Partnership Business Wire

Mar 25, 2021

08:02AM EDT Horizon Therapeutics Enrolls First Patient In FORWARD Trial To Evaluate Monthly Dosing Of KRYSTEXXA And Methotrexate To Treat Uncontrolled Gout Benzinga

Mar 24, 2021

08:21AM EDT Horizon : Japan Approves UPLIZNA For Prevention Of Relapses Of Neuromyelitis Optica Spectrum Disorder RTTNews

08:18AM EDT Horizon Therapeutics Announces Its Partner Mitsubishi Tanabe Pharma Corporation Has Received Manufacturing And Marketing Approval For UPLIZNA By The Japanese Ministry of Health, Labour And Welfare Benzinga

08:15AM EDT UPLIZNA(r) (inebilizumab-cdon) Approved by Japanese Ministry of Health, Labour and Welfare for the Prevention of Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD) Business Wire

08:00AM EDT Horizon Therapeutics plc Launches The Horizon Prize with Massachusetts Institute of Technology (MIT) Solve to Advance Solutions for the Rare Disease Community Business Wire

Mar 22, 2021

08:27AM EDT Morgan Stanley Reinstates Overweight on Horizon Therapeutics, Announces $103 Price Target Benzinga

Mar 18, 2021

08:50AM EDT Citigroup Maintains Buy on Horizon Therapeutics, Announces $120 Price Target Benzinga

Mar 17, 2021

10:08AM EDT Stifel Maintains Buy on Horizon Therapeutics, Raises Price Target to $125 Benzinga

Mar 15, 2021

08:53AM EDT Horizon Therapeutics Completes Acquisition Of Viela Bio RTTNews

08:50AM EDT Horizon Therapeutics plc Completes Acquisition of Viela Bio, Inc. Business Wire

Mar 12, 2021

08:56AM EST Wolfe Research Initiates Coverage On Horizon Therapeutics with Outperform Rating, Announces Price Target of $107 Benzinga

08:45AM EST Horizon Therapeutics plc Named Number One Best Workplace in Biopharma Business Wire

Mar 11, 2021

03:00AM EST Horizon Therapeutics plc Named as One of the Best Workplaces in Ireland Business Wire

Feb 26, 2021

04:05PM EST Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference Business Wire

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

07:23AM EST Horizon Therapeutics Q4 EPS $0.82; Non-GAAP EPS $1.28 RTTNews

07:22AM EST Recap: Horizon Therapeutics Q4 Earnings Benzinga

07:12AM EST Horizon Therapeutics Sees FY21 Sales $2.7B-$2.80B vs $2.68B Est. Benzinga

07:11AM EST Horizon Therapeutics Q4 Adj. EPS $1.28 Beats $1.05 Estimate, Sales $745.30M Beat $690.03M Estimate Benzinga

07:00AM EST Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance Business Wire

03:35AM EST Earnings Scheduled For February 24, 2021 Benzinga

Feb 22, 2021

09:31AM EST Horizon Therapeutics Reports Results Of A New Thyroid Eye Disease Quality Of Life Assessment Presented At North American Neuro-Ophthalmology Society Meeting Benzinga

09:30AM EST New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase Business Wire

Feb 20, 2021

08:34PM EST (VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are PR Newswire

Feb 17, 2021

12:09PM EST Jefferies Maintains Buy on Horizon Therapeutics, Raises Price Target to $120 Benzinga

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 3, 2021

08:00AM EST Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021 Business Wire

Feb 1, 2021

03:12PM EST SHAREHOLDER ALERT: WeissLaw LLP Investigates Viela Bio, Inc. PR Newswire

02:06PM EST Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Viela Bio, Inc. (NASDAQ: VIE) breached their fiduciary duties or violated the federal securities laws in connection with the companys acquisition by Horizon Therapeutics plc (NASDAQ: HZNP). GlobeNewswire Inc

09:37AM EST (VIE Alert) Johnson Fistel Investigates Proposed Sale of Viela Bio; Are PR Newswire

07:17AM EST Horizon Therapeutics To Buy Viela Bio For $53/Shr Cash - RTTNews

07:07AM EST Viela Bio to be Acquired by Horizon Therapeutics for $53/Share in Cash Benzinga

07:06AM EST Horizon Therapeutics To Acquire Viela Bio For $53/Shr Cash Or Fully Diluted Equity Value Of $3.05 Bln RTTNews

07:00AM EST Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio Business Wire

04:00AM EST Earnings Scheduled For February 1, 2021 Benzinga

Jan 29, 2021

10:05AM EST Horizon Therapeutics Earnings Preview Benzinga

Jan 11, 2021

07:21AM EST Horizon Therapeutics Says FY Net Sales Exceeded High End Of Guidance Range Of $2.12 Bln To $2.14 Bln RTTNews

07:17AM EST Horizon Therapeutics Says 2020 Sales & EBITDA Will Exceed Previously Given Guidance Benzinga

07:00AM EST Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA(r) (teprotumumab-trbw) Supply and New KRYSTEXXA(r) (pegloticase injection) Trials Business Wire

Dec 22, 2020

08:00AM EST Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 17, 2020

06:44AM EST Horizon Therapeutics Announces Short-Term TEPEZZA Supply Disruption Due To Govt-Mandated COVID-19 Vaccine Production RTTNews

06:40AM EST Horizon Therapeutics plc Announces Short-Term TEPEZZA(r) (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production Business Wire

06:17AM EST UPDATE: Horizon Does Not Expect Short-Term Supply Disruption To Impact FY20 Financial Guidance Benzinga

06:17AM EST Horizon Therapetuics 8-K Shows Expectation For Short-Term Distribution In TEPEZZA Supply As A Result Of COVID-19 Vaccine Production Orders Related To Warp Speed To Have 'dramatically restricted capacity available for the production...' Benzinga

Dec 3, 2020

09:00AM EST Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education Business Wire

Dec 2, 2020

09:15AM EST Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List Business Wire

Nov 30, 2020

08:00AM EST Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities Business Wire

Nov 25, 2020

08:00AM EST Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire

Nov 23, 2020

08:11AM EST Horizon Therapeutics Plc And Halozyme Enter Global Collaboration And License Deal For ENHANZE Technology RTTNews

08:07AM EST Halozyme Licenses' its Drug Delivery Technology to Horizon Theerapeutics, Halozyme Receive $30M Upfront Payment Benzinga

08:01AM EST Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global PR Newswire

08:00AM EST Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE(r) Technology Business Wire

Nov 17, 2020

09:15AM EST National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation Business Wire

Nov 16, 2020

10:54AM EST First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease Business Wire

Nov 13, 2020

08:37AM EST Horizon : New TEPEZZA Data Suggests Benefits Of TEPEZZA In Less Severe Eye Of Patients With Thyroid Eye Disease RTTNews

08:32AM EST Horizon Therapeutics Highlights Presentation Of TEPEZZA Data At American Academy Of Ophthalmology Annual Meeting Benzinga

08:30AM EST New Data Build on Growing Evidence Supporting TEPEZZA(r) (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration Business Wire

Nov 12, 2020

08:00AM EST Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire

Nov 2, 2020

02:02PM EST Horizon Therapeutics Announces Higher Response Rates In RECIPE Randomized Controlled Trial Of KRYSTEXXA Concomitantly Used With The Immunomodulator Mycophenolate Mofetil Benzinga

08:12AM EST Horizon Therapeutics: Q3 Earnings Insights Benzinga

07:55AM EST Earnings Scheduled For November 2, 2020 Benzinga

07:11AM EST Horizon Therapeutics Q3 Net Sales $636.4 Mln, Increase of 90% From Last Year RTTNews

07:07AM EST Horizon Therapeutics Raises FY20 Sales Guidance From $1.85B-$1.90B to $2.12B-$2.14B vs $1.95B Est. Benzinga

07:05AM EST Horizon Therapeutics Q3 Adj. EPS $1.74 Beats $0.94 Estimate, Sales $636.43M Beat $517.68M Estimate Benzinga

07:04AM EST Horizon Therapeutics Raises Guidance Benzinga

07:01AM EST Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA(r) Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance Business Wire

06:58AM EST Horizon Therapeutics plc Names Karin Rosn, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer Business Wire

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

09:15AM EDT Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year Business Wire

08:08AM EDT Horizon Therapeutics To Present TEPEZZA Data At American Academy Of Ophthalmology Annual Meeting Nov. 13-15 Benzinga

08:00AM EDT New TEPEZZA(r) (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting Business Wire

Oct 29, 2020

03:04PM EDT AGC Biologics, Horizon Therapeutics Expand Partnership Benzinga

03:00PM EDT AGC Biologics and Horizon Therapeutics plc Expand Partnership PR Newswire

08:06AM EDT Horizon Therapeutics Plc Initiates Clinical Trial To Assess Shorter Infusion Duration For KRYSTEXXA (Pegloticase Injection) Concomitantly Used With Methotrexate To Treat Uncontrolled Gout Benzinga

Oct 26, 2020

08:00AM EDT Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain's Chicago Business Business Wire

Oct 23, 2020

08:00AM EDT Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption Business Wire

Oct 22, 2020

10:03AM EDT Horizon Therapeutics Highlights Will Offer Initial Findings From PROTECT Study At Kidney Week 2020 Benzinga

Oct 20, 2020

08:00AM EDT Horizon Therapeutics plc Announces TEPEZZA(r) (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award Business Wire

Oct 16, 2020

08:30AM EDT FORTUNE and Great Place to Work(r) Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year Business Wire

Oct 14, 2020

08:10AM EDT Horizon Therapeutics Reports New Long-Term Follow-Up Data From Phase 2 Trial Of TEPEZZA Showed Sustained Response Up To 1 Year Following Completion Of Treatment For Thyroid Eye Disease Benzinga

08:00AM EDT TEPEZZA(r) (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED) Business Wire

Oct 8, 2020

08:19AM EDT Horizon Therapeutics To Present Data Evaluating KRYSTEXXA At American College Of Rheumatology Convergence 2020 Nov. 5-9 Benzinga

08:00AM EDT Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020 Business Wire

Oct 7, 2020

08:00AM EDT Horizon Therapeutics plc Named One of San Francisco Bay Area's Best and Brightest Companies to Work For Business Wire

Oct 5, 2020

08:00AM EDT Horizon Therapeutics plc Announces TEPEZZA(r) (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award Business Wire

Sep 16, 2020

08:13AM EDT Horizon Therapeutics Highlights Open-Label Trial Data Published In Journal Of Rheumatology Showed 79% Of Patients Achieved Complete Response Using KRYSTEXXA With Methotrexate Benzinga

Sep 13, 2020

02:25PM EDT Cramer Advises Viewers On Applied Materials, Blackstone And More Benzinga

Sep 9, 2020

09:45AM EDT Benzinga's Top Upgrades, Downgrades For September 9, 2020 Benzinga

06:18AM EDT JP Morgan Initiates Coverage On Horizon Therapeutics with Overweight Rating, Announces Price Target of $110 Benzinga

Sep 2, 2020

09:00AM EDT Horizon Therapeutics plc Named to the 2020 PEOPLE "50 Companies That Care" List Business Wire

Sep 1, 2020

08:00AM EDT Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire

Aug 27, 2020

01:25PM EDT Horizon Therapeutics shares are trading higher after Citigroup initiated coverage on the stock with a Buy rating and a $112 price target. Benzinga

09:55AM EDT Benzinga's Top Upgrades, Downgrades For August 27, 2020 Benzinga

06:42AM EDT Citigroup Initiates Coverage On Horizon Therapeutics with Buy Rating, Announces Price Target of $112 Benzinga

Aug 11, 2020

05:00PM EDT Horizon Therapeutics plc Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Ordinary Shares Business Wire

Aug 10, 2020

09:15AM EDT Morgan Stanley Maintains Overweight on Horizon Therapeutics, Raises Price Target to $90 Benzinga

09:00AM EDT Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain's Chicago Business Business Wire

Aug 6, 2020

11:31PM EDT Horizon Therapeutics Prices Public Offering Of 11.80 Mln Shares At $71.00/shr RTTNews

11:20PM EDT Horizon Therapeutics plc Announces Pricing of Public Offering of Ordinary Shares Business Wire

11:26AM EDT BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to $105 Benzinga

09:00AM EDT Horizon Therapeutics Named 2020 Top Workplace for Millennials by Fortune Business Wire

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

Share